Differential clinical prognostic classifications in dilated and ischemic advanced heart failure:: The EPICAL study

被引:58
作者
Alla, F
Briançon, S
Juillière, Y
Mertes, PM
Villemot, JP
Zannad, F
机构
[1] Univ Hosp, Dept Epidemiol, Nancy, France
[2] Univ Hosp, Dept Cardiol, Nancy, France
[3] Univ Hosp, INSERM, CIC, Nancy, France
[4] Lorraine Hosp, Nancy, France
关键词
D O I
10.1016/S0002-8703(00)90023-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The clinical management of severe congestive heart failure (CHF) should be graded according to the prognosis of each individual patient. Our objective was to elaborate a prognostic rating system For severe CHF. Methods The EPICAL program (Epidemiologie de I'Insuffisance Cardiaque Avancee en Lorraine) identified patients with severe CHF defined by hospitalization accompanied by class III/IV dyspnea, edema, or hypertension; an ejection fraction less than or equal to 30% or a cardiothoracic index greater than or equal to 60%. Baseline variables were tested in Cox multivariate models. Results Patients with ischemic heart disease (n = 219) had a lower 1-year survival rate (57.6%) than patients with dilated cardiomyopathy (n = 182) (69.1%). Multivariate analysis identified 5 prognostic factors for ischemic CHF and 7 for CHF caused by dilated cardiomyopathy. These variables were used to classify patients within prognostic subgroups of good (>75%), intermediate, or poor(less than or equal to 25%) 1-year survival. Conclusion A score for prognostic prediction was further derived from readily available data ia help physicians improve decision making and to assist in clinical trials as a stratification tool.
引用
收藏
页码:895 / 904
页数:10
相关论文
共 33 条
  • [1] Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation
    Aaronson, KD
    Schwartz, JS
    Chen, TM
    Wong, KL
    Goin, JE
    Mancini, DM
    [J]. CIRCULATION, 1997, 95 (12) : 2660 - 2667
  • [2] CLINICAL AND HEMODYNAMIC PREDICTORS OF SURVIVAL IN PATIENTS AGED LESS-THAN-65 YEARS WITH SEVERE CONGESTIVE-HEART-FAILURE SECONDARY TO ISCHEMIC OR NONISCHEMIC DILATED CARDIOMYOPATHY
    ANGUITA, M
    ARIZON, JM
    BUENO, G
    LATRE, JM
    SANCHO, M
    TORRES, F
    GIMENEZ, D
    CONCHA, M
    VALLES, F
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (05) : 413 - 417
  • [3] BIGGER JT, 1987, CIRCULATION, V75, P28
  • [4] BROPHY JM, 1994, CAN J CARDIOL, V10, P543
  • [5] A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)
    Califf, RM
    Adams, KF
    McKenna, WJ
    Gheorghiade, M
    Uretsky, BF
    McNulty, SE
    Darius, H
    Schulman, K
    Zannad, F
    HandbergThurmond, E
    Harrell, FE
    Wheeler, W
    SolerSoler, J
    Swedberg, K
    [J]. AMERICAN HEART JOURNAL, 1997, 134 (01) : 44 - 54
  • [6] CAMPANA C, 1993, J HEART LUNG TRANSPL, V12, P756
  • [7] CHASTANG C, 1980, B CANCER, V67, P430
  • [8] PLASMA NOREPINEPHRINE AS A GUIDE TO PROGNOSIS IN PATIENTS WITH CHRONIC CONGESTIVE HEART-FAILURE
    COHN, JN
    LEVINE, TB
    OLIVARI, MT
    GARBERG, V
    LURA, D
    FRANCIS, GS
    SIMON, AB
    RECTOR, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (13) : 819 - 823
  • [9] COHN JN, 1993, CIRCULATION S, V87, P15
  • [10] Risk stratification in chronic heart failure
    Cowburn, PJ
    Cleland, JGF
    Coats, AJS
    Komajda, M
    [J]. EUROPEAN HEART JOURNAL, 1998, 19 (05) : 696 - 710